Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Bayer and Dewpoint Therapeutics partner to research new treatments for cardiovascular and gynecological diseases

Bayer and biotechnology company Dewpoint Therapeutics announced an option, research and license agreement worth up to $100 million.

Read More »

Cellectis Publishes Creation of “Smart CAR T-Cells” for Potentially Safer, More Effective Treatments for Cancer

Cellectis announced a paper published in Nature Communications that describes a proof-of-concept for rewiring the cell pathway to create highly intelligent T-cells that can recognize cancerous tumors and cause a micro secretion of therapeutic proteins onto these tumors, which ultimately reshapes the tumor microenvironment and improves the T-cells ability to fight cancer.

Read More »

Kiadis to Restructure Months After Acquiring CytoSen

Netherlands-based Kiadis Pharma is discontinuing Phase III development of lead T-cell asset ATIR101 and laying off half of the company’s staff, seven months after acquiring CytoSen.

Read More »

Solid Biosciences shares plummet as gene therapy trial halted again

Shares in Solid Biosciences Inc. plunged 71 percent after a clinical trial testing the company’s gene therapy for a muscle-wasting disorder was halted for the second time in less than two years.

Read More »

FDA Approves Rare Blood Disease Treatment Reblozyl

The U.S. FDA approved Celgene and Acceleron Pharma’s Reblozyl for the treatment of anemia in adult patients with beta thalassemia who require regular red blood cell (RBC) transfusions.

Read More »

Novartis gets U.S. nod for long-delayed Amgen copycat

Novartis won FDA approval for a long-delayed version of Amgen’s $4 billion seller Neulasta drug, helping the Swiss drugmaker in an uphill battle to sell copies of rivals’ blockbusters in the U.S.

Read More »

Breast Cancer: Steady Progress Being Made in New Treatments

For Breast Cancer Awareness Month, BioSpace gathered examples of recent breakthroughs in breast cancer treatment.

Read More »

Dicerna, Roche Partner on RNA Silencing for Hep B

Cambridge, Mass.-based Dicerna Pharmaceuticals signed a research collaboration and licensing deal with Switzerland’s Roche for chronic hepatitis B virus therapies that could hit $1.67 billion.

Read More »

Breast cancer drug gets FDA priority review

The U.S. drug regulator will give a speedy review to AstraZeneca Plc’s experimental breast cancer treatment trastuzumab deruxtecan.

Read More »

GammaDelta Therapeutics Spins Out Adaptate Bio to Develop Gammadelta T-Cells

London-based GammaDelta Therapeutics announced the spin-out of Adaptate Biotherapeutics, which will focus on developing an immune response to cancer.

Read More »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

October 2019 Focus: Top 50 Company Profiles & Financials, Outcomes Creativity Index, and more!


Ad Right Bottom